Health
Drug Compound Targets Weakness in Advanced Prostate Cancer – Technology Networks
A new study reports that prostate cancer cells with a deletion of the SUCLA2 gene can be therapeutically targeted using the compound thymoquinone.
The compound thymoquinone (TQ) selectively kills prostate cancer cells at advanced stages, according to a new study published in Oncogene. Led by researchers at Kanazawa University, the study reports that prostate cancer cells with a deletion of the SUCLA2 gene can be therapeutically targeted. SUCLA2-deficient prostate cancers represent a significant fraction of those resistant to hormone therapy or metastatic, and a new therapeutic option for this disease would have immense benefits for patient…
-
Business22 hours agoForget CBA and buy these high-yield ASX dividend shares
-
General23 hours agoWhy an Australian journalist is teaching meditation in America’s toughest jails
-
Noosa News23 hours ago“There’s No Going Back”: The Grid Meets the Real World in the Initial Trailer for Third ‘TRON’ Movie ‘Ares’
-
Business23 hours agoTop brokers name 3 ASX shares to buy next week 6 April 2025